GlaxoSmithKline PLC (GSK)

GSK (NYSE:Drugs) EQUITY
$42.76
neg -0.60
-1.40%
Today's Range: 42.82 - 43.33 | GSK Avg Daily Volume: 3,776,900
Last Update: 04/29/16 - 2:18 PM EDT
Volume: 2,008,951
YTD Performance: 7.46%
Open: $43.21
Previous Close: $43.36
52 Week Range: $37.24 - $46.76
Oustanding Shares: 2,680,653,823
Market Cap: 116,528,021,686
6-Month Chart
TheStreet Ratings Grade for GSK
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 2 2 2 4
Moderate Buy 0 0 0 0
Hold 4 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 1 1 1 1
Mean Rec. 2.71 2.71 2.71 2.33
Latest Dividend: 1.22
Latest Dividend Yield: 5.40%
Dividend Ex-Date: 02/17/16
Price Earnings Ratio: 24.98
Price Earnings Comparisons:
GSK Sector Avg. S&P 500
24.98 8.50 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
6.69% -7.80% -16.87%
GROWTH 12 Mo 3 Yr CAGR
Revenue -1.00 -0.20 -0.06
Net Income 181.50 0.60 0.17
EPS 189.50 0.70 0.20
Earnings for GSK:
EBITDA 5.79B
Revenue 35.44B
Average Earnings Estimates
Qtr (06/16) Qtr (09/16) FY (12/16) FY (12/17)
Average Estimate $0.60 $0.74 $2.57 $2.68
Number of Analysts 1 1 6 5
High Estimate $0.60 $0.74 $2.78 $2.94
Low Estimate $0.60 $0.74 $2.44 $2.53
Prior Year $0.53 $0.71 $2.26 $2.57
Growth Rate (Year over Year) 13.21% 4.23% 13.86% 4.07%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands
CEO Read says the Viagra maker retains the means to pursue 'attractive business development' opportunities as he tears up the six-month-old deal with the maker of Botox.
With the short-term trend neutral and the longer-term trend down be on guard for a break lower to around $35.
Dividend yield is the determining factor in this strategy.

Novice Trade: GlaxoSmithKline Real Money Pro($)

Owning GSK May calls may give a nice payout on any good news regarding a Zika virus vaccine.
If you have an appetite for risk, there are buying opportunities.
Cempra and Relypsa are two high-risk, high-reward small-caps worth considering.
This trio enjoys competitive advantages that should serve investors well over the long haul.
Use $24 or $26 as a stop point. 

Columnist Conversations

The Biotech iShares (IBB) ETF has broken through support at the $270.00 level and is testing its 50 day moving...
I bought some more shares of Interface (TILE) just now at $16.95. TILE looks good for a move into the $23 - $...
Biotech is having a very tough day, as investors react to the first miss in 9 quarters from Gilead Sciences (G...
1. Unmasking Zero Hedge 2. Tech as In Wreck (I really think this is a good column , at least I enjoyed writing...

REAL MONEY'S BEST IDEAS

News Breaks

Powered by

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.